Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: Effect of fiber- immobilized polymyxin B treatment

American Journal of the Medical Sciences

Volumn 316, Issue 6, 1998, Pages 355-360

  Nakamura, Tsukasa ^a   Ebihara, Isao ^b   Shimada, Noriaki ^b   Shoji, Hisataka ^c   Koide, Hikaru ^b  

^a Misato Junshin Hospital   (Japan)

^b KOTO HOSPITAL   (Japan)

^c Toray Medical Company   (Japan)

Author keywords

Endotoxin; Extracellular matrix; Fiber immobilized polymyxin B; Inflammation; Metalloproteinase; Septic shock

Indexed keywords

CYTOKINE; ENDOTOXIN; GELATINASE B; INTERLEUKIN 1BETA; MESSENGER RNA; POLYMYXIN B; TORAYMYXIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; EXTRACELLULAR MATRIX; HEMOPERFUSION; HUMAN; MONOCYTE; PROGNOSIS; SEPTIC SHOCK;

EID: 0032430765     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199812000-00001     Document Type: Article

References (37)

1. Wilhelm SM, Collier IE, Manner BL, Eisen AZ, Grant GA, Goldberg GI. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 1989;264:17213-22.
2. Senior RM, Griffin GL, Fliazar CJ, Shapiro SD, Goldberg GI, Welgus HG. Human 92-and 72-kilodalton type IV collagenases are elastase. J Biol Chem. 1991;266:7870-5.
3. Okada Y, Gonoji Y, Naka K, Tomita K, Nakanishi I, Iwata K, et al. Matrix metalloproteinase 9 from HT 1080 human fibrosarcoma cells: purification and activation of the precursor, and enzymic properties. J Biol Chem. 1992;267: 21712-9.
4. Moutsiakis D, Mancuso P, Krutzsch H, Stetler-Stevenson W, Zucker S. Characterization of metalloproteinases and tissue inhibitors of metalloproteinase in human plasma. Connect Tissue Res. 1992;28:213-30.
5. r 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 1993;53:140-6.
6. Ballin M, Gomez DE, Sinha CC, Thomgeirsson UP. Ras oncogene-mediated induction of a 92 kDa metalloproteinase: strong correlation with the malignant phenotype. Biochem Biophys Res Commun. 1988;154:832-8.
7. Tryggavason K, Hoyhtya M, Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res Treat. 1993;24:209-18.
8. Hibbs MS. Expression of 92 kDa phagocyte gelatinase by inflammatory and connective tissue cells. Matrix 1992; 1(suppl):51-7.
9. Fujimoto N, Hosokawa N, Iwata K, Shinya T, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase-9 using monoclonal antibodies. Clin Chim Acta. 1994;231:79-88.
10. Torii A, Kodera Y, Uesaka K, Hirai T, Yasui K, Morimoto N, et al. Matrix metalloproteinase-9 in human plasma has 96% specificity and 56% sensitivity for gastric cancer screening. Int Clin Oncol. 1996;1:39-43.
11. Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR, et al. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol. 1996;78: 161-71.
12. Welgus HG, Campbell EJ, Cury JD, Eisen AZ, Senior RM, Wilhelm SM, et al. Neutral metalloproteinases produced by human mononuclear phagocytes: enzyme profile, regulation and expression during cellular development. J Clin Invest. 1990;86:1496-502.
13. Koide H, Nakamura T, Ebihara I, Tomino Y. Increased mRNA expression of MMP-9 in peripheral blood monocytes from patients with immunoglobulin A nephropathy Am J Kidney Dis. 1996;28:32-9.
14. Endo S, Inada K, Inoue Y, Kuwata Y, Suzuki M, Yamashita H, et al. Two types of septic shock classified by the plasma levels of cytokines and endotoxin. Circ Shock. 1992; 38:264-74.
15. Hanasawa K, Tani T, Kodama M. New approach to endotoxic and septic shock by means of polymyxin B immobilized fiber. Surgery. 1989;168:323-31.
16. Aoki H, Kodama M, Tani T, Hanasawa K. Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg. 1994;167:412-7.
17. Abel J, Spannbrucker N, Fandrey J, Jelkmann W. Serum erythropoietin levels in patients with sepsis and septic shock. Eur J Haematol. 1996;57:359-63.
18. Knaus W, Draper E, Wagner EP, Zimmermann EJ. APACHE II: A severity of disease classification system. Crit Care Med. 1985;13:818-29.
19. Ebihara I, Nakamura T, Suzuki S, Tomino Y, Koide H. Proto-oncogene expression in peripheral blood mononuclear cells in IgA nephropathy. Kidney Int. 1991;39:946-53.
20. Nakamura T, Ebihara I, Shirato I, Fukui M, Tomino Y, Koide H. Endothelin-1 mRNA expression by peripheral blood monocytes in IgA nephropathy. Lancet 1993;342: 1147-8.
21. Collier IE, Wilhelm SM, Eizen AZ, Manner BL, Grant GA, Kronberger A, et al. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloproteinase capable of degrading basement membrane collagen. J Biol Chem. 1988;263:6579-87.
22. Feinberg AP, Vogelstein B. A technique for radiolabeling restriction endonuclease fragments to high specific activity Anal Biochem. 1983;132:6-13.
23. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci USA. 1984;81:1991-5.
24. Mulligan MS, Varani J, Dame MK, Lane CL, Smith CW Anderson DC, et al. Role of endothelial-leukocyte adhesion molecule (ELAM-1) in neutrophil-mediated lung injury in rats. J Clin Invest. 1991;88:1396-1406.
25. Kuster H, Degitz K. Circulating ICAM-1 in neonatal sepsis Lancet. 1993;341:506.
26. Endo S, Inada K, Kasai T, Takakuwa T, Yamada Y, Koike S, et al. Levels of soluble adhesion molecules and cytokines in patients with septic multiple organ failure J Inflamm. 1996;46:211-9.
27. Nakamura T, Suzuki Y, Shimada N, Ebihara I, Shoji H, Koide H. Hemoperfusion with polymixin B-immobilized fiber attenuates the increased plasma levels of thrombomodulin and von Willebrand factor from patients with septic shock. Blood Purif (in press).
28. Hibbs MS, Hoidal JR, Kang AH. Expression of a metalloproteinase that degrades native type IV collagen and denatured collagens by cultured human alveolar macrophages J Clin Invest. 1987;80:1644-50.
29. Murphy G, Ward R, Hembry RM, Reynolds JJ, Kuhn K, Tryggavason K. Characterization of gelatinase from pig polymorphonuclear leukocytes. Biochem J. 1989;258: 463-72.
30. Wahl SM, Allen JB, Weeks BS, Wong HL, Klotman PE. Transforming growth factor-β enhances integrin expression and type IV collagenase secretion in human monocytes. Proc Natl Acad Sci USA. 1993;90:4577-81.
31. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990;6:121-8.
32. Damas P, Canivert JL, Groote DD, Vrindts Y, Albert A, Franchimont P, et al. Sepsis and serum cytokine concentrations. Crit Care Med. 1997;25:405-12.
33. Debets JMH, Kampmeijer R, Van der Linden MPMH, Buurman WA, Van der Linden CJ. Plasma tumor necrosis factor and mortality in critical ill septic patients. Crit Care Med. 1989;17:489-94.
34. Offner F, Phillipe J, Vogelaers D, Colardyn F, Baele G, Baudrihaye M, et al. Serum tumor necrosis factor levels in patients with infectious disease and septic shock J Lab Clin Med. 1990;116:100-5.
35. De Groote MA, Martin MA, Densen P, Pfaller MA, Wenzel RP. Plasma tumor necrosis factor levels in patients with presumed sepsis. JAMA. 1989;262:249-51.
36. Marano MA, Fong Y, Moldawer LL, Wei H, Calvano SE, Tracey KJ, et al. Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet. 1990;170:32-8.
37. Shimada N, Abe S, Hishiki T, Maehiro K, Ono Y, Daidoji H, et al. Reduction of plasma nitric oxide in patients with endotoxic shock by hemoadsorption therapy. Nephron. 1997; 75:115.